C12N 2760/16043
Viral genome or elements thereof as genetic vector
Official title: viral genome or elements thereof as genetic vector
C12N2760/16043 (Viral genome or elements thereof as genetic vector) appears on 17 US grants and 29 published applications in this corpus.
Search patents in C12N- Granted patents
- 17
- Published applications
- 29
- Assignees
- 17
- Inventors
- 49
- Latest grant
- 24 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 1 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 3 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 2 | 0 |
| 2010 | 0 | 1 |
| 2011 | 1 | 2 |
| 2012 | 0 | 1 |
| 2013 | 0 | 1 |
| 2014 | 2 | 1 |
| 2015 | 1 | 1 |
| 2016 | 1 | 2 |
| 2017 | 1 | 0 |
| 2018 | 0 | 2 |
| 2019 | 2 | 2 |
| 2020 | 1 | 2 |
| 2021 | 0 | 0 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 2 | 2 |
| 2025 | 1 | 2 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes24 Feb 2026US 12,559,717 B2The Board of Trustees of the Leland Stanford Junior University
- Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes12 Aug 2025US 12,385,010 B2The Board of Trustees of the Leland Stanford Junior University
- Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes24 Dec 2024US 12,173,314 B2The Board of Trustees of the Leland Stanford Junior University
- Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes8 Oct 2024US 12,110,504 B2The Board of Trustees of the Leland Stanford Junior University
- Plasmids and method for obtaining viral particles28 Jan 2020US 10,544,398 B2Universidad de Santiago de Chile
- Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes4 Jun 2026US 2026/0152720 A1The Board of Trustees of the Leland Stanford Junior University
- Neddylation-activating enzyme inhibitors as viral sensitizers and uses thereof15 Jan 2026US 2026/0015592 A1Ottawa Hospital Research Institute
- Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes14 Aug 2025US 2025/0257319 A1The Board of Trustees of the Leland Stanford Junior University
- Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes6 Mar 2025US 2025/0075178 A1The Board of Trustees of the Leland Stanford Junior University
- Or2l13 agonists to treat cvd with dysregulated platelet activation4 Apr 2024US 2024/0108591 A1The Cleveland Clinic Foundation
Most cited
By later US patents
- Methods of use of viral vectors to deliver antigen to dendritic cells43US 6,300,090 B1The Rockefeller University · 2001
- Recombinant influenza vectors with tandem transcription units41US 7,968,101 B2Wisconsin Alumni Research Foundation · 2011
- Viruses encoding mutant membrane protein33US 7,588,769 B2Wisconsin Alumni Research Foundation · 2009
- Methods of use of viral vectors to deliver antigen to dendritic cells22US 6,455,299 B1The Rockefeller University · 2002
- Recombinant influenza vectors with tandem transcription units17US 8,877,209 B2Wisconsin Alumni Research Foundation · 2014